Bone health and body composition in transgender adults before gender-affirming hormonal therapy: data from the COMET study
-
Published:2023-07-14
Issue:
Volume:
Page:
-
ISSN:1720-8386
-
Container-title:Journal of Endocrinological Investigation
-
language:en
-
Short-container-title:J Endocrinol Invest
Author:
Ceolin C.ORCID, Scala A., Dall’Agnol M., Ziliotto C., Delbarba A., Facondo P., Citron A., Vescovi B., Pasqualini S., Giannini S., Camozzi V., Cappelli C., Bertocco A., De Rui M., Coin A., Sergi G., Ferlin A., Garolla A., Garolla Andrea, Aprile Anna, Azzena Bruno, Barbisan Camillo, Camozzi Valentina, Campello Elena, Annamaria Cattelan, Ceolin Chiara, Moro Fabrizio, Conti Giorgio, Favaro Angela, Ferlin Alberto, Francini Francesco, Gatta Michela, Ghisi Marta, Giannini Sandro, Guazzarotti Laura, Iafrate Massimo, Meneguzzo Paolo, Miscioscia Marina, Ottaviano Giancarlo, Saccardi Carlo, Sasset Lolita, Scala Alberto, Schiavo Rossana, Sergi Giuseppe, Simioni Paolo, Tascini Benedetta, Venturini Francesca, Vianello Fabrizio,
Abstract
Abstract
Purpose
Preliminary data suggested that bone mineral density (BMD) in transgender adults before initiating gender-affirming hormone therapy (GAHT) is lower when compared to cisgender controls. In this study, we analyzed bone metabolism in a sample of transgender adults before GAHT, and its possible correlation with biochemical profile, body composition and lifestyle habits (i.e., tobacco smoke and physical activity).
Methods
Medical data, smoking habits, phospho-calcic and hormonal blood tests and densitometric parameters were collected in a sample of 125 transgender adults, 78 Assigned Females At Birth (AFAB) and 47 Assigned Males At Birth (AMAB) before GAHT initiation and 146 cisgender controls (57 females and 89 males) matched by sex assigned at birth and age. 55 transgender and 46 cisgender controls also underwent a complete body composition evaluation and assessment of physical activity using the International Physical Activity Questionnaire (IPAQ).
Results
14.3% of transgender and 6.2% of cisgender sample, respectively, had z-score values < -2 (p = 0.04). We observed only lower vitamin D values in transgender sample regarding biochemical/hormonal profile. AFAB transgender people had more total fat mass, while AMAB transgender individuals had reduced total lean mass as compared to cisgender people (53.94 ± 7.74 vs 58.38 ± 6.91, p < 0.05). AFAB transgender adults were more likely to be active smokers and tend to spend more time indoor. Fat Mass Index (FMI) was correlated with lumbar and femur BMD both in transgender individuals, while no correlations were found between lean mass parameters and BMD in AMAB transgender people.
Conclusions
Body composition and lifestyle factors could contribute to low BMD in transgender adults before GAHT.
Funder
Università degli Studi di Padova
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference47 articles.
1. Coleman E, Radix AE, Bouman WP et al (2022) Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgender Heal 23(sup1):S1–S259. https://doi.org/10.1080/26895269.2022.2100644 2. Fisher AD, Senofonte G, Cocchetti C et al (2022) SIGIS-SIAMS-SIE position statement of gender affirming hormonal treatment in transgender and non-binary people. J Endocrinol Invest 45(3):657–673. https://doi.org/10.1007/S40618-021-01694-2 3. Van Caenegem E, Wierckx K, Taes Y et al (2015) Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study. Osteoporos Int Published online. https://doi.org/10.1007/s00198-014-2805-3 4. Porcelli T, Maffezzoni F, Pezzaioli LC, Delbarba A, Cappelli C, Ferlin A (2020) Management of endocrine disease: male osteoporosis: diagnosis and management - should the treatment and the target be the same as for female osteoporosis? Eur J Endocrinol 183(3):R75–R93. https://doi.org/10.1530/EJE-20-0034 5. Wiepjes CM, de Jongh RT, de Blok CJM et al (2019) Bone safety during the first ten years of gender-affirming hormonal treatment in transwomen and transmen. J Bone Miner Res 34(3):447–454. https://doi.org/10.1002/jbmr.3612
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|